jurnalul român de psihofarmacologie romanian journal of ...

240. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine.
Hospital and Community Psychiatry 1990; 41:882-885.
241. Jonsson D, Walinder J. Cost-effectiveness of clozapine treatment in therapy-refractory
schizophrenia. Acta Psychiatr Scand 1995; 92:199-201.
242. Meltzer JY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B. Costeffectiveness
of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;
150:1630-1638.
243. Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW. Current topics in clinical
psychopharmacology. Economic outcomes of antipsychotic agents in a Medicaid
population: traditional agents versus risperidone. Psychopharmacology Bulletin 1998a;
34:373-382.
244. Nightengale BS, Garrett L, Waugh S, Bryan RN, Lawrence J. Economic outcomes
associated with the use of risperidone in a naturalistic group practice setting. Am J
Managed Care 1998b; 4:360-366.
245. Obenchain RL, Johnstone BM. Mixed model imputation of cost data for early discontinuers
from a randomized clinical trial. Drug Information Journal 1999; 33:191-207.
246. Revicki DA. Pharmacoeconomic evaluation of treatments of refractory schizophrenia:
clozapine-related studies. Journal of Clinical Psychiatry 1999; 60(Suppl. 1):7-11,
discussion 28-30.
247. Revicki DA, Genduso L, Hamilton SH, Ganozcy D, Beasly CM. Olanzapine versus haloperidol
in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical
outcomes of a randomized clinical trial. Quality of Life Research 1999; 8:417-426.
248. Rosenheck R, Cramer J, Allan E, Erdos J, Friesman LW, Xu W, Thomas J, Henderson W,
Charney D. Cost effectiveness of clozapine in patients with high and low levels of hospital
use. Arch Gen Psychiatry 1999; 56:565-572.
249. Sacristan JA, Gomez JC, Martin J. Pharmacoeconomic assessment of olanzapine in the
treatment of refractory schizophrenia based on a pilot clinical study. Clinical Drug
Investiogations 1998; 15:29-35.
250. Schiller MJ, Shumway M, Hargreaves WA. Treatment costs and patient outcomes with use
of risperidone in a public mental health setting. Psychiatric Services 1999; 50:228-232.
251. Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived
health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol
treatment of schizophrenia. J Clin Psychiatry 1999; 60(Suppl. 19):38-45.
252. MedWatch 2002 Safety Information alert at: http://www.fda.gov/medwatch/SAFETY/2002/
safety02.htm#clozar.
152